Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
Apellis Pharmaceuticals, Inc. insider activity: Chief Executive Officer and director Cedric Francois reported selling 27,192 shares of Apellis common stock on January 22, 2026 at a price of $21.7654 per share. The filing explains that this sale was made to cover tax withholding on restricted stock units that were released on January 21, 2026. After this transaction, Francois directly held 286,045 Apellis shares.
In addition to his direct holdings, the filing lists indirect holdings in several trusts, including 307,946 shares held by The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares held by The Cedric Francois Irrevocable Trust of 2023, 300,000 shares held by The Francois Grossi Trust, and 234,411 shares held by The Francois-DuBois Educational Trust. These shares are held by the respective trusts, and Francois disclaims beneficial ownership except to the extent of any pecuniary interest.
Apellis Pharmaceuticals chief technical officer files insider share sale
Apellis Pharmaceuticals chief technical officer Nur Nicholson reported selling 7,725 shares of Apellis common stock on January 22, 2026 at a price of $21.7654 per share. According to the filing, these shares were sold to cover tax withholding obligations arising from Restricted Stock Units that were released on January 21, 2026. After this transaction, Nicholson beneficially owned 71,118 shares of Apellis common stock held directly.
Apellis Pharmaceuticals, Inc. Chief Financial Officer Timothy Eugene Sullivan reported a sale of 10,287 shares of common stock on January 22, 2026. The shares were sold at a price of $21.7654 per share and the filing explains that this sale was made to cover tax withholding on Restricted Stock Units that were released on January 21, 2026.
After this tax‑related sale, Sullivan directly beneficially owned 93,901 shares of Apellis common stock. In addition, 60,396 shares are held indirectly through The Timothy E Sullivan Irrevocable Trust of 2023. The filing notes that the securities in the trust are held by that trust with Patrick O. Collins as trustee, and Sullivan disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest in them.
Apellis Pharmaceuticals General Counsel David O. Watson reported a sale of company common stock in an insider filing. On January 22, 2026, he sold 7,832 shares of Apellis common stock at $21.7654 per share, and the filing explains this sale was made to cover tax withholding on Restricted Stock Units that were released on January 21, 2026. After this transaction, he directly holds 88,531 common shares.
The filing also lists indirect holdings. A custodial account held by him for the sole benefit of his minor children holds 10,000 common shares50,136 common shares are held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The Watson Education Trust is shown with 0 shares, and he likewise disclaims beneficial ownership in that trust except for any pecuniary interest.
An individual holder of APLS common stock has filed a Rule 144 notice to sell 7,832 shares. The planned sale is to be executed through Fidelity Brokerage Services LLC on or about 01/22/2026 on the NASDAQ, with an indicated aggregate market value of $170,466.61. The filing notes that 126,525,218 shares of this class were outstanding.
The shares to be sold were acquired on 01/21/2026 via restricted stock vesting from the issuer as compensation, in the same amount of 7,832 shares. The notice also lists prior sales of APLS common stock by David O. Watson over the past three months, including transactions on 11/17/2025, 12/16/2025, 01/13/2026, and 01/20/2026 with gross proceeds ranging from about $48,987.43 to $128,242.01. The signer represents that they do not know of any undisclosed material adverse information about the issuer.
A shareholder of the company with symbol APLS has filed a notice of proposed sale of 5,928 shares of common stock under Rule 144. The shares, to be sold through Fidelity Brokerage Services LLC on the NASDAQ, have an aggregate market value of $129,025.30, while common shares outstanding are listed as 126,525,218. The shares were acquired on 01/21/2026 through restricted stock vesting from the issuer as compensation.
The filing also lists prior sales in the last three months by Pascal Deschatelets, who sold 2,277 common shares on 01/13/2026 for gross proceeds of $50,520.25 and 909 common shares on 01/20/2026 for $17,991.75. By signing the notice, the selling person represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
APLS insider Timothy E. Sullivan has filed a notice of proposed sale under Rule 144 for 10,287 shares of common stock, to be sold through Fidelity Brokerage Services on NASDAQ around 01/22/2026. The filing lists an aggregate market value of $223,900.67 for these shares and notes that 126,525,218 shares of the same class were outstanding at the time of the notice. The shares to be sold were acquired on 01/21/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Sullivan sold 3,856 shares for $85,553.84 on 01/13/2026 and 2,892 shares for $57,241.07 on 01/20/2026.
Apellis Pharmaceuticals insider plans to sell additional shares under Rule 144. A notice was filed for the proposed sale of 3,371 shares of Apellis common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 73,371.17 and 126,525,218 shares outstanding.
The shares to be sold were acquired on 01/21/2026 through restricted stock vesting from the issuer as compensation. In the past three months, Mark J. Delong has already sold 1,780 shares for 39,493.22 on 01/13/2026 and 1,334 shares for 26,403.73 on 01/20/2026. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about Apellis.
APLS insider plans a new stock sale under Rule 144. A notice was filed to sell 27,192 shares of common stock through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/22/2026. The filing lists an aggregate market value of 591,844.76 for these shares and notes that 126,525,218 common shares are outstanding.
The 27,192 shares to be sold were acquired on 01/21/2026 through restricted stock vesting from the issuer as compensation, with payment also dated 01/21/2026. The notice also reports prior sales over the past three months by Cedric Francois at the same address, including 10,186 common shares sold on 01/13/2026 for gross proceeds of 225,998.82 and 8,182 common shares sold on 01/20/2026 for gross proceeds of 161,945.51. The signer represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
APLS shareholder Nur Nicholson has filed a Rule 144 notice to sell 7,725 shares of common stock. The shares are to be sold through Fidelity Brokerage Services on the NASDAQ exchange, with an aggregate market value of $168,137.72 based on the figures in the notice. The filing lists 126,525,218 common shares outstanding and targets an approximate sale date of January 22, 2026.
The 7,725 shares were acquired on January 21, 2026 through restricted stock vesting from the issuer as compensation. The notice also shows that over the prior three months, Nicholson sold 2,618 and 2,203 common shares on January 13 and January 20, 2026, for gross proceeds of $58,086.09 and $43,603.76, respectively. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.